Company Acticor Biotech SAS

Equities

ALACT

FR0014005OJ5

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

End-of-day quote Euronext Paris Other stock markets 06:00:00 2024-04-28 pm EDT			5-day change	1st Jan Change
0.41 ^EUR	+22.02%		-89.27%	-85.86%

08:00am	Acticor Biotech SAS Announces Postponement in Publication of 2023 Annual Results	CI
Apr. 26	Acticor Biotech: rebound from the previous day's tumble	CF

Acticor Biotech is specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms.

The group has one product in Phase II/III clinical development (Glenzocimab).

Number of employees: 29

Managers	Title	Age	Since
Gilles Avenard FOU	Founder	-	13-11-25
Eric Cohen DFI	Director of Finance/CFO	-	-
Adeline Meilhoc CTO	Chief Tech/Sci/R&D Officer	-	-
Andrea Comenducci CTO	Chief Tech/Sci/R&D Officer	-	18-10-31
Aymeric Humblot ADM	Chief Administrative Officer	-	-
Sophie Binay CTO	Chief Tech/Sci/R&D Officer	-	-
Yannick Plétan CTO	Chief Tech/Sci/R&D Officer	-	17-12-19
James Stearns PRN	Corporate Officer/Principal	-	-
Jessica Jami LAW	General Counsel	-	19-10-31
Philippe Billiald PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Gilles Avenard FOU	Founder	-	13-11-25
Catherine Boule BRD	Director/Board Member	-	-
Alain Munoz CHM	Chairman	75	21-06-14
Alain Parthoens BRD	Director/Board Member	64	18-10-23
Rinaldo del Bono BRD	Director/Board Member	-	-
Guy Heynen BRD	Director/Board Member	-	-
Patricia Zilliox BRD	Director/Board Member	-	23-01-25
Philippe Billiald PRN	Corporate Officer/Principal	-	-
Leila Nicolas BRD	Director/Board Member	-	-
Jean-Pierre Cazenave BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	12,338,781	12,338,781 ( 100.00 %)	0	100.00 %

Name	Equities	%	Valuation
Friedland Gestion SAS 0.2351 %	37,045	0.2351 %	128 428 €
Olympia Wealth Management Ltd. 0.0190 %	3,000	0.0190 %	10 400 €

Acticor Biotech SAS

Bâtiment Inserm U1148 Hôpital Bichat

75877, Paris

+33 6 76 23 38 13

http://www.acticor-biotech.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.41 EUR

Average target price

10 EUR

Spread / Average Target

+2,339.02%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ACTICOR BIOTECH SAS	-85.86%	5.77M
VERTEX PHARMACEUTICALS INCORPORATED	-2.91%	102B
REGENERON PHARMACEUTICALS, INC.	+1.84%	96.29B
ARGENX SE	+2.01%	22.18B
BIONTECH SE	-15.13%	21.2B
GENMAB A/S	-9.03%	18.31B
WUXI APPTEC CO., LTD.	-39.98%	17.38B
BEIGENE, LTD.	-14.38%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.59%	13.97B
SAREPTA THERAPEUTICS, INC.	+32.26%	12.17B

Bio Therapeutic Drugs